Results 71 to 80 of about 104,817 (211)

Deep Learning‐Powered Scalable Cancer Organ Chip for Cancer Precision Medicine

Advanced Science, EarlyView.
This scalable, low‐cost Organ Chip platform, made via injection molding, uses capillary pinning for hydrogel confinement and supports versatile tissue coculture and robust imaging. Deep learning enables label‐free, sensitive phenotypic analysis.
Yu‐Chieh Yuan, Beibei Xu, Jenna McCormack, XuHai Huang, Jingzhe Ma, Thomas Marshall, Yacong Sun, Hardeep Singh, Alyssa Fanelli, Gauri Kulkarni, Ji Hye Seo, Paige Gilbride, Bing Wei, Bo Wang, Yanyan Liu, Fei Ma, Lin Zhou, Shuyang Wang, Xiaohua Qian, Zhiyong Xie, Polina Golland, Longlong Si, Yu Shrike Zhang, Xin Xie, Haiqing Bai   +24 more
wiley   +1 more source

Oncolytic Probiotics with Molecular Pili for Solid Tumor Therapy

Advanced Science, EarlyView.
This study identifies Lactobacillus rhamnosus as an intrinsic oncolytic agent that triggers tumor metabolic collapse via calcium‐dependent ROS bursts. By chemically anchoring collagen‐targeting “molecular pili” to the bacterial surface, the engineered non‐transgenic probiotic (LR@MP) achieves targeted colonization and potent solid tumor suppression ...
Haodong Ge, Chengsheng Ding, Xiao Yang, Si Gao, Changjie Yang, Yuchen Hou, Hongye Wang, Linke Bian, Hao Zhong, Yifan Qu, Luyang Zhang, Junjun Ma, Zhengwei Cai, Wenguo Cui, Minhua Zheng   +14 more
wiley   +1 more source

Temozolomide and Pazopanib Combined with FOLFOX Regressed a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. [PDF]

, 2020
PurposeThe goal of the present study was to determine the efficacy of temozolomide (TEM) and pazopanib (PAZ) combined with FOLFOX (oxaliplatin, leucovorin and 5-fluorouracil) on a colorectal cancer patient-derived orthotopic xenograft (PDOX) mouse model ...
Bouvet, Michael, Clary, Bryan, Han, Qinghong, Hoffman, Robert M, Singh, Shree Ram, Sun, Yu, Tan, Yuying, Ye, Jianxin, Zhao, Ming, Zhu, Guangwei   +9 more
core  

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Upregulation of ERK phosphorylation in rat dorsal root ganglion neurons contributes to oxaliplatin-induced chronic neuropathic pain.

PLoS ONE, 2019
Oxaliplatin is the first-line chemotherapy for metastatic colorectal cancer. Unlike other platinum anticancer agents, oxaliplatin does not result in significant renal impairment and ototoxicity.
Toyoaki Maruta, Takayuki Nemoto, Koutaro Hidaka, Tomohiro Koshida, Tetsuro Shirasaka, Toshihiko Yanagita, Ryu Takeya, Isao Tsuneyoshi   +7 more
doaj   +1 more source

Metformin protects from oxaliplatin induced peripheral neuropathy in rats

Neurobiology of Pain, 2020
Oxaliplatin is a commonly used drug to treat cancer, extending the rate of disease-free survival by 20% in colorectal cancer. However, oxaliplatin induces a disabling form of neuropathy resulting in more than 60% of patients having to reduce or ...
N.W. Martinez, A. Sánchez, P. Diaz, R. Broekhuizen, J. Godoy, S. Mondaca, A. Catenaccio, P. Macanas, B. Nervi, M. Calvo, F.A. Court   +10 more
doaj   +1 more source

Intense endoplasmic reticulum stress (ERS) / IRE1α enhanced Oxaliplatin efficacy by decreased ABCC10 in colorectal cancer cells

BMC Cancer, 2022
Background Attenuated Oxaliplatin efficacy is a challenge in treating colorectal cancer (CRC) patients, contributory to the failure in chemotherapy and the risks in relapse and metastasis.
Xiaohui Liu, Bo Wu, Hong Chen, Haimei Sun, Xiaoxia Guo, Tingyi Sun, Deshan Zhou, Shu Yang   +7 more
doaj   +1 more source

ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair [PDF]

, 2008
Background: The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum-drug resistance. Resistance was not associated with increased cellular glutathione or decreased accumulation of platinum, rather the resistant cell lines have a cell
A Husain, A Sancar, B Stordal, BK Stordal, Britta Stordal, C Richardson, CH Hensel, DW Melton, E Raderschall, ER McDonald III, ES Child, F Nunez, FM Wachters, G Bepler, H Lincet, HD Preisler, IY Chang, JC Harrison, JJ Yu, JS Russell, K Rothkamm, KA Olaussen, KM Darcy, L Poulain, LF Qin, LF Qin, M Dabholkar, M Takata, M Takata, PA Havre, PA Havre, R Altaha, R Napieralski, R Rosell, RG Sargent, RG Syljuasen, Ross Davey, RVN Lord, S Henness, S Rozen, SG Chaney, T Hata, TT Paull, Y Yonetani   +43 more
core   +2 more sources

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats. [PDF]

PLoS ONE, 2015
Oxaliplatin has widely been used as a key drug in the treatment of colorectal cancer; however, it causes peripheral neuropathy. Exenatide, a glucagon-like peptide-1 (GLP-1) agonist, is an incretin mimetic secreted from ileal L cells, which is clinically ...
Shunsuke Fujita, Soichiro Ushio, Nana Ozawa, Ken Masuguchi, Takehiro Kawashiri, Ryozo Oishi, Nobuaki Egashira   +6 more
doaj   +1 more source